Rigel to Participate at the RBC Capital Markets Healthcare Conference
To access the live audio webcast or the subsequent archived recording, logon to http://www.rigel.com. Please connect to Rigel's website several minutesprior to the start of the live webcast to ensure adequate time for anysoftware download that may be necessary.
About Rigel (http://www.rigel.com)
Rigel is a clinical-stage drug development company that discovers anddevelops novel, small-molecule drugs for the treatment ofinflammatory/autoimmune diseases and cancer, as well as viral and metabolicdiseases. Our pioneering research focuses on intracellular signaling pathwaysand related targets that are critical to disease mechanisms. Rigel'sproductivity has resulted in strategic collaborations with largepharmaceutical partners to develop and market our product candidates. Rigelhas product development programs in inflammatory/autoimmune diseases such asrheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.
Contact: Ryan Maynard
SOURCE Rigel Pharmaceuticals, Inc.
You May Also Like